Zoetis Inc. $ZTS Shares Purchased by Leelyn Smith LLC

Leelyn Smith LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,450 shares of the company’s stock after purchasing an additional 881 shares during the period. Leelyn Smith LLC’s holdings in Zoetis were worth $3,813,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after acquiring an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in shares of Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after acquiring an additional 312,746 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $146.14 on Friday. The firm has a 50 day simple moving average of $148.18 and a 200-day simple moving average of $153.50. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $64.77 billion, a PE ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $184.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio is 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several analyst reports. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Friday. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.